Julio Gay-Ger – President & General Manager, Lilly China
Julio Gay-Ger, an industry and Eli Lilly veteran, shares how he is leveraging on his 23 years of experience managing Lilly affiliates in LATAM to deliver on Lilly’s objective to…
Address: Unit 4107B, Tower 1, Plaza 66,
1266 Nanjing West Road,
Jing An District,
Shanghai 200040
China
Tel: +86 21 6057 0700
Web: http://www.biogenidec.com/
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, we are the world’s oldest independent biotechnology company and a Fortune 500 company with more than $5 billion in annual revenues. Patients worldwide benefit from our leading multiple sclerosis therapies.
That’s one perspective on Biogen Idec, though it is not the only one.
To our patients, we are the trusted source of vital therapies for multiple sclerosis, such as AVONEX® and TYSABRI®. We also discovered RITUXAN®, the world’s most prescribed treatment for non-Hodgkin’s lymphoma and an effective treatment for rheumatoid arthritis. Our patients count on us not only for medications, but also for a variety of support programs that help them deal with the rigors of living with serious illness.
To our employees, we are an exciting and invigorating place to work, an ambitious and nimble company where courageous innovation is encouraged and expected — not just of scientists but of every employee. Our manufacturing people take pride in our leadership in producing biologics, with more than 100,000 liters of capacity spread across three facilities. Our customer service representatives handle more than 800,000 calls per year, offering straightforward information, assistance and patient services. Across the company, in marketing, sales, quality control and human resources, people are empowered to challenge conventional wisdom and propose better ways of doing things.
To our partners and investors, we are a profitable company with a rich and diverse pipeline. We have the resources, financial strength and vision to successfully discover, develop, manufacture and commercialize new products.
And to our friends, neighbors and the world at large, we are a responsible corporate citizen with robust programs that make our communities better places to live and work and address critical issues like diversity and sustainability.
Biogen Idec is all these companies. We are dedicated to serving all our constituents, because Biogen Idec is in business to make a difference for all those we serve.
Research and development, MS, Oncology
Julio Gay-Ger, an industry and Eli Lilly veteran, shares how he is leveraging on his 23 years of experience managing Lilly affiliates in LATAM to deliver on Lilly’s objective to…
Yan Hao, chairman and CEO of EPS Group shares the company’s journey to become Japan’s largest and most comprehensive provider of optimal outsourced solutions to the healthcare industry through its…
Asgar Rangoonwala, president of Xian Janssen, Janssen’s Chinese affiliate, shares the key milestones for the affiliate in the past two years, how Janssen is investing in bringing new innovations to…
Dr Jun Bao, appointed president and CEO of Impact Therapeutics in October 2018, shares his aspirations for Impact to be a leader in synthetic lethality in oncology; the importance of…
Click here to register and download PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: China. From the world’s ninth largest pharma market in 2007 to its second-biggest merely 12…
Lorena Di Carlo, a Lundbeck veteran, shares her first impressions of her six months as general manager of Lundbeck China, the strategic significance of China to Lundbeck’s global organization, the…
China’s unbridled growth has spurred a vast number of overseas Chinese to return home to seek new opportunities in their transformed homeland. Affectionately known as ‘sea turtles’ because the Chinese…
Dr John Yu, co-founder and CEO of CGeneTech, shares the exciting story behind the company’s establishment in 2010; its balanced philosophy on new drug development and the progress of their…
Fendy Yanhui Feng, vice president of Eisai Co., Ltd. and president of Eisai China Holdings Ltd. and Eisai China Inc., shares the significant improvements she has made to Eisai’s China…
Research has established that proper nutrition during hospitalization helps to reduce the number of infections, the duration of treatment needed for recovery, and reduce the readmission rateCecily Gu discusses her…
Samantha Du, Chairman and CEO of Zai Lab, the flagship China biotech company, shares her inspirational story of being one of the pioneers to forge a path for Chinese biopharma…
Lydia Guo, Grace Zhao and Mendy Zhang of executive search firm Egon Zehnder outline some of the latest trends affecting the Chinese pharma sector and what they look for in…
See our Cookie Privacy Policy Here